Impact of CTNNB1 Alterations on Outcomes in Patients with Hepatocellular Carcinoma HCC

Authors:

Jonathan Pai, Yasmine Baca, Rituparna Ganguly, Mehmet Akce, Sandra Algaze, Lydia Chow, Ani Misirian, Diana Hanna, Heinz-Josef Lenz, John Marshall, Syma Iqbal, Rachna Shroff, Mitesh Borad, Anthony El-Khoueiry

Background:

  • The WNT/beta catenin (CTNNB1) pathway plays an integral role in the development of HCC.•CTNNB1 has been implicated in HCC progression, metastasis, and drug resistance.
  • The impact of CTNNB1 alterations on prognosis and efficacy of immunotherapy and tyrosine kinase inhibitors in HCC is unclear.
  • We examined associations between CTNNB1 mutations and mRNA expression and clinical outcomes in a real-world cohort of patients with HCC.
Download Publication